Experience
Defending a leading pharmaceutical company in a patent infringement suit brought against its widely used innovative cancer products.
Representing an R&D company in patent litigation regarding the company’s patents developed in connection with research on treatments for viral diseases.
Representing a small biopharmaceutical company in its efforts to bring to market an innovative small-molecule therapeutic offering significant advantages to patients over prior treatments in the face of patent litigation filed by a competitor.
Representing a global innovative biotechnology company in PTAB proceedings brought against the company’s patents on novel combination therapies.
(District of Delaware). Defended Dropworks, a digital PCR start-up, in patent litigation brought by Bio-Rad.
(District of Delaware). Represented 10x Genomics, a life sciences technology company and a worldwide leader in genomics, in a patent infringement suit against Celsee.
(District of Delaware). Defended Edwards Lifesciences in a patent infringement action relating to Edwards’ PASCAL device, a novel transcatheter treatment option for mitral and tricuspid regurgitation.
(District of Delaware). Defended Genentech in patent infringement litigation brought against its cancer treatment Tecentriq®, the first anti-PD-L1 antibody approved to treat cancer.
(District of Delaware, Federal Circuit, and Supreme Court). Represented Vanda in Hatch-Waxman litigation regarding proposed generic versions of Vanda’s FANAPT® product. Obtained a victory at trial that was affirmed on appeal in a widely-cited opinion.
(C.D. Cal.). Represented Genentech and City of Hope in a series of challenges brought against their ground-breaking “Cabilly” patents, which covered the foundational method of manufacturing monoclonal antibodies.